Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: Is radiotherapy necessary after D2-dissection?

Table 1 Major patient characteristics and results of phase III trials of postoperative radiotherapy for gastric cancer

Ref.	n	Enrolled period	Median F/u (m)	pT3-4	pN+	III-IV	D2	OS	DFS/RFS	Remarks
SWOG/INT-0116[3]	556	91-98	60	70%	85%	NR	10%	3-yr: 50% vs 41%(P = 0.005)	3-yr: 48% vs 31%(P < 0.001)	Similar benefit in 10-yr follow-up data
ARTIST[6]	458	04-08	53	NR	86%	41%	100%	NR	3-yr: 78% vs 74%(P = 0.0862)	DFS benefit in N+
NCC, South Korea[7]	90	02-06	87	63%	98%	100%	100%	5-yr: 65% vs 55%(P > 0.05)	5-yr: 61% vs 50%(P > 0.05)	LRRFS benefit(DFS benefit in stage III)
IMRT, China[8]	351	03-08	43	NR	86%	71%	Majority	5-yr: 48% vs 42%(P = 0.122)	5-yr: 45% vs 36%(P = 0.029)

F/u: Follow-up; PS: Performance status; NR: Not reported; OS: Overall survival; DFS/RFS: Disease-free survival/relapse-free survival; LRRFS: Loco-regional failure-free survival.